Dickson Dennis W, Braak Heiko, Duda John E, Duyckaerts Charles, Gasser Thomas, Halliday Glenda M, Hardy John, Leverenz James B, Del Tredici Kelly, Wszolek Zbigniew K, Litvan Irene
Mayo Clinic, Jacksonville, FL, USA.
Lancet Neurol. 2009 Dec;8(12):1150-7. doi: 10.1016/S1474-4422(09)70238-8.
To date, there have been few systematic attempts to provide a standard operating procedure for the neuropathological diagnosis of Parkinson's disease (PD). Pathological examination cannot classify the clinical syndrome with certainty; therefore, the neuropathological diagnosis is, at best, a probability statement. The neuropathological diagnosis of parkinsonism has become increasingly based on fundamental molecular underpinnings, with recognition that the genetics of parkinsonism is heterogeneous and includes disorders that are associated with and without Lewy bodies. The advent of alpha-synuclein immunohistochemistry has substantially improved the ability to identify Lewy pathology, particularly cortical Lewy bodies and smaller aggregates within processes and the neuropil. In this Review we discuss the diagnostic criteria for the neuropathological assessment of PD. These criteria are provisional and need to be validated through an iterative process that could help with their refinement. Additionally, we suggest future directions for neuropathology research on PD.
迄今为止,几乎没有系统的尝试来提供帕金森病(PD)神经病理学诊断的标准操作程序。病理检查无法确定地对临床综合征进行分类;因此,神经病理学诊断充其量只是一种概率性陈述。帕金森病的神经病理学诊断越来越基于基本的分子基础,同时认识到帕金森病的遗传学是异质性的,包括与路易小体相关和不相关的疾病。α-突触核蛋白免疫组织化学的出现极大地提高了识别路易病理的能力,特别是皮质路易小体以及突起和神经毡内较小的聚集体。在本综述中,我们讨论了PD神经病理学评估的诊断标准。这些标准是临时性的,需要通过一个迭代过程进行验证,这有助于对其进行完善。此外,我们还提出了PD神经病理学研究的未来方向。